Posts
The National Association of People
With AIDS (NAPWA) strongly supports
today's move by the United States Food and Drug Administration to approve use
of Truvada (emtricitabine/ tenofovir disoproxil fumarate) for pre-exposure
prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection.
"It's time for people at high
risk of HIV infection to be empowered to protect themselves and others,"
said Frank J. Oldham, Jr., NAPWA's President and CEO. "Today's approval of
Truvada for HIV prevention gives them an important new tool to do that.
"PrEP is not a final solution
to the spread of HIV," Oldham continued, "but it can be one tool, and
a very useful one, in a well stocked toolkit of prevention measures. We urge
all Americans to assess their HIV risk realistically and use condoms if they
are at risk, but we thank the FDA for approving Truvada for PrEP for those who
cannot or will not."
The Friends of AIDS Foundation is
dedicated to enhancing the quality of life for HIV positive individuals and
empowering people to make healthy choices to prevent the spread of the HIV
virus. To learn more about The Friends of AIDS Foundation, please visit: http://www.friendsofaids.org.
TOGETHER WE REMAIN STRONG!
